342 related articles for article (PubMed ID: 20883781)
1. Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.
Schmidt LJ; Tindall DJ
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):32-8. PubMed ID: 20883781
[TBL] [Abstract][Full Text] [Related]
2. Dutasteride for the treatment of prostate-related conditions.
Slater S; Dumas C; Bubley G
Expert Opin Drug Saf; 2012 Mar; 11(2):325-30. PubMed ID: 22316171
[TBL] [Abstract][Full Text] [Related]
3. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
[TBL] [Abstract][Full Text] [Related]
4. A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia.
Sun J; Xiang H; Yang LL; Chen JB
Curr Med Chem; 2011; 18(23):3576-89. PubMed ID: 21756226
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
[TBL] [Abstract][Full Text] [Related]
6. [Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks].
MMW Fortschr Med; 2003 Feb; 145(9):54. PubMed ID: 12666533
[No Abstract] [Full Text] [Related]
7. Dutasteride for the treatment of benign prostatic hyperplasia.
Wu C; Kapoor A
Expert Opin Pharmacother; 2013 Jul; 14(10):1399-408. PubMed ID: 23750593
[TBL] [Abstract][Full Text] [Related]
8. Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
Pirozzi L; Sountoulides P; Castellan P; Presicce F; Lombardo R; Romero M; De Nunzio C; Tubaro A; Schips L; Cindolo L
Curr Drug Targets; 2015; 16(11):1165-71. PubMed ID: 25981606
[TBL] [Abstract][Full Text] [Related]
9. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
Arena F
Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
[TBL] [Abstract][Full Text] [Related]
10. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
[TBL] [Abstract][Full Text] [Related]
11. [Dutasteride in the treatment of benign prostatic hyperplasia: an update].
Chen HJ; Chen YR
Zhonghua Nan Ke Xue; 2011 Jan; 17(1):63-7. PubMed ID: 21351536
[TBL] [Abstract][Full Text] [Related]
12. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
Issa MM; Runken MC; Grogg AL; Shah MB
Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
[TBL] [Abstract][Full Text] [Related]
13. Hormonal manipulation of benign prostatic hyperplasia.
Rick FG; Saadat SH; Szalontay L; Block NL; Kazzazi A; Djavan B; Schally AV
Curr Opin Urol; 2013 Jan; 23(1):17-24. PubMed ID: 23202285
[TBL] [Abstract][Full Text] [Related]
14. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
15. Dutasteride and prostate cancer.
Garattini S; Bertele' V
N Engl J Med; 2010 Aug; 363(8):794; author reply 794-6. PubMed ID: 20842790
[No Abstract] [Full Text] [Related]
16. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
17. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.
Azzouni F; Mohler J
Urology; 2012 Jun; 79(6):1197-205. PubMed ID: 22446342
[TBL] [Abstract][Full Text] [Related]
18. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
19. Evolving role of 5-alpha reductase inhibitors in chemoprevention.
White WM; Kim ED
Nat Rev Clin Oncol; 2010 Sep; 7(9):487-8. PubMed ID: 20798697
[No Abstract] [Full Text] [Related]
20. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
Dolder CR
Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
